Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Nanobiotix S.A. (NBTX)

3.45   0.1 (2.99%) 03-17 10:40
Open: 3.45 Pre. Close: 3.35
High: 3.45 Low: 3.36
Volume: 114 Market Cap: 120(M)

Technical analysis

as of: 2023-03-24 4:28:13 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 4.56     One year: 4.95
Support: Support1: 3.35    Support2: 2.79
Resistance: Resistance1: 3.9    Resistance2: 4.24
Pivot: 3.55
Moving Average: MA(5): 3.53     MA(20): 3.59
MA(100): 3.87     MA(250): 4.33
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 8.9     %D(3): 19.7
RSI: RSI(14): 41.9
52-week: High: 7.53  Low: 2.31
Average Vol(K): 3-Month: 1 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NBTX ] has closed above bottom band by 26.0%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.46 - 3.48 3.48 - 3.49
Low: 3.31 - 3.34 3.34 - 3.35
Close: 3.42 - 3.45 3.45 - 3.48

Company Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Headline News

Wed, 15 Feb 2023
SERA stock jumps as study for preterm birth test succeeds ... - Seeking Alpha

Tue, 14 Feb 2023
Voting Rights and Shares Capital of the Company - GlobeNewswire

Thu, 02 Feb 2023
AKBA stock jumps after FDA nod for GSK kidney disease therapy ... - Seeking Alpha

Tue, 03 Jan 2023
Sesen Bio investors plan to vote against Carisma merger(NASDAQ ... - Seeking Alpha

Wed, 28 Dec 2022
AKBA stock on watch after licensing deal for ferric citrate product ... - Seeking Alpha

Mon, 26 Dec 2022
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 35 (M)
% Held by Insiders 2.977e+007 (%)
% Held by Institutions 0 (%)
Shares Short 3 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.76e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 795.8
Return on Equity (ttm) -29.2
Qtrly Rev. Growth 2.66e+006
Gross Profit (p.s.) 0.44
Sales Per Share -110.39
EBITDA (p.s.) 1.47222e+006
Qtrly Earnings Growth -1.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -32 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 5.21

Stock Dividends

Dividend 0
Forward Dividend 1840
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.